株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の点眼薬市場 (ドライアイ、緑内障、感染症/炎症、網膜疾患など) :産業分析、規模、シェア、成長率、動向、予測

Ophthalmic Drugs Market (Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, & Others; Therapeutic Class; Product Type; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025

発行 Transparency Market Research 商品コード 294619
出版日 ページ情報 英文 243 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。
Back to Top
世界の点眼薬市場 (ドライアイ、緑内障、感染症/炎症、網膜疾患など) :産業分析、規模、シェア、成長率、動向、予測 Ophthalmic Drugs Market (Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, & Others; Therapeutic Class; Product Type; Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025
出版日: 2017年07月25日 ページ情報: 英文 243 Pages
概要

当レポートでは、世界の点眼薬市場について調査分析し、産業分析、市場規模と予測、セグメント別の市場分析、地域別の市場分析、競合情勢など、体系的な情報を提供しています。

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 主な市場指標
  • 市場力学
  • 世界の点眼薬市場の分析と予測
  • ファイブフォース分析
  • 市場の見通し
  • 世界の企業シェア分析:緑内障
  • パイプライン分析:主要企業
  • パイプライン分析:新興企業
  • 主要製品の比較マトリクス:主要企業
  • スナップショット:失明の原因 - 世界
  • スナップショット:失明の原因 - 地域

第5章 世界の点眼薬市場の分析と予測:疾患適応別

  • イントロダクション・定義
  • 主な調査結果/発展
  • 主要動向
  • 市場価格予測:疾患適応別
  • 市場の魅力分析:疾患適応別

第6章 世界の点眼薬市場の分析と予測:薬効分類別

  • イントロダクション・定義
  • 主な調査結果/発展
  • 主要動向
  • 市場価格予測:薬効分類別
  • 市場の魅力分析:薬効分類別

第7章 世界の点眼薬市場の分析と予測:製品タイプ別

  • イントロダクション・定義
  • 主な調査結果/発展
  • 主要動向
  • 市場価格予測:製品タイプ別
  • 市場の魅力分析:製品タイプ別

第8章 世界の点眼薬市場の分析と予測:流通経路別

  • イントロダクション・定義
  • 主な調査結果/発展
  • 主要動向
  • 市場価格予測:流通経路別
  • 市場の魅力分析:流通経路別

第9章 世界の点眼薬市場の分析と予測:地域別

  • 主な調査結果
  • 政策・規制
  • 市場価格予測:地域別
  • 市場の魅力:国/地域別

第10章 北米の点眼薬市場の分析と予測

第11章 欧州の点眼薬市場の分析と予測

第12章 アジア太平洋地域の点眼薬市場の分析と予測

第13章 ラテンアメリカの点眼薬市場の分析と予測

第14章 中東・アフリカの点眼薬市場の分析と予測

第15章 競合情勢

  • 市場企業:競合マトリクス
  • 市場シェア分析:企業別
  • 企業プロファイル
    • Aerie Pharmaceuticals, Inc.
    • ALLERGAN
    • aleant Pharmaceuticals International, Inc.
    • Bayer AG
    • Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • 参天製薬
    • Shire
    • その他

第16章 要点

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Title:
Ophthalmic Drugs Market
(Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular Degeneration, Dry Age-related Macular Degeneration, and Diabetic Retinopathy), Allergy, and Uveitis; Therapeutic Class - Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs and Anti-bacterial Drugs), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, and Combined Medication), Anti-allergy Drugs, and Anti-VEGF Agents; Product Type - Prescription Drugs and Over-the-Counter Drugs; Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Ophthalmic Drugs Market: Overview

Ophthalmic drugs is a growing market driven by rising prevalence of intraocular eye disorders mainly in elderly population like glaucoma, cataract, age-related macular degeneration, diabetic retinopathy, etc. Also, there is an increasing incidence of eye diseases globally such as dry eye, conjunctivitis, uveitis, and others, and the number of patients suffering from eye diseases is expected to grow exponentially during the forecast period. As a result of this increasing patient pool across the globe, major market players are increasing R&D investments to capture the significant commercial opportunity through innovations in treatment methods, and improvement in drug's mechanism of action with novel biological agents.

The market overview section of the report comprises qualitative analysis of the overall ophthalmic drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, therapeutic class, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The company share analysis has also been provided for global glaucoma drug market. The pipeline analysis of major as well as emerging market players has been given in the market overview section, along with the product comparison matrix of the major market players. The report also consists of a section depicting the major causes of blindness globally, as well as by regions.

Global Ophthalmic Drugs Market: Segmentation

The global ophthalmic drugs market is segmented in terms of disease indication, therapeutic class, product type, and distribution channels. The disease indication segment is further classified into dry eye, glaucoma, infection/inflammation, retinal disorders, allergy, uveitis, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Among the disease indication segment, the retinal disorders segment accounted for the largest share of the global ophthalmic drugs market in 2016, owing to factors like exponentially rising patient pool demanding long-term treatment. However, the dry eye segment is expected to grow at a high CAGR during the forecast period, due to changing environmental conditions, pollutions, etc.

In terms of therapeutic class, global ophthalmic drugs market is divided into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF agents, and others. The anti-inflammatory drugs segment is bi-furcated into nonsteroidal anti-inflammatory drugs, and steroids. The anti-infective drugs are further sub-segmented into anti-fungal drugs, anti-bacterial drugs, and others. The anti-glaucoma drugs segment is classified into alpha agonist, beta blockers, prostaglandin analogs, combined medication, and others. On the basis of product type, the market is segmented into prescription drugs and OTC drugs. Based on distribution channels, the global ophthalmic drugs market is segmented into hospital pharmacies, online pharmacies, and independent pharmacies & drug stores.

Geographically, the ophthalmic drugs market has been categorized into five regions namely: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of disease indication, therapeutic class, product type, and distribution channels, along with the CAGR (%) for the forecast period 2017 to 2025.

Global Ophthalmic Drugs Market: Competitive Analysis

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global ophthalmic drugs market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global ophthalmic drugs market such as Aerie Pharmaceuticals, Inc., ALLERGAN, Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Shire among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

Global Ophthalmic Drugs Market is segmented as follows:

Global Ophthalmic Drugs Market, by Disease Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
  • Wet Age-related Macular Degeneration
  • Dry Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Others
  • Allergy
  • Uveitis
  • Others

Global Ophthalmic Drugs Market, by Therapeutic Class

  • Anti-inflammatory Drugs
  • Nonsteroidal Anti-inflammatory Drugs
  • Steroids
  • Anti-infective Drugs
  • Anti-fungal Drugs
  • Anti-bacterial Drugs
  • Others
  • Anti-glaucoma Drugs
  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

Global Ophthalmic Drugs Market, by Product Type

  • Prescription Drugs
  • Over-the-Counter Drugs

Global Ophthalmic Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies & Drug Stores

Global Ophthalmic Drugs Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Disease Indication Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
    • 4.4.4. Trends
  • 4.5. Global Ophthalmic Drugs Market Analysis and Forecasts, 2015-2025
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Porter's Five Force Analysis
  • 4.7. Market Outlook
  • 4.8. Global Company Share Analysis: Glaucoma; 2016
  • 4.9. Pipeline Analysis: Major Market Players
  • 4.10. Pipeline Analysis: Emerging Market Players
  • 4.11. Comparison matrix for product offerings: Major Market Players
  • 4.12. Snapshot: Causes of blindness - Global
  • 4.13. Snapshot: Causes of blindness - Regional

5. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market Value Forecast by Disease Indication, 2015-2025
    • 5.4.1. Dry Eye
    • 5.4.2. Glaucoma
    • 5.4.3. Infection/Inflammation
    • 5.4.4. Retinal Disorders
      • 5.4.4.1. Wet AMD
      • 5.4.4.2. Dry AMD
      • 5.4.4.3. Diabetic Retinopathy
      • 5.4.4.4. Others
    • 5.4.5. Allergy
    • 5.4.6. Uveitis
    • 5.4.7. Others
  • 5.5. Market Attractiveness by Disease Indication

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market Value Forecast By Therapeutic Class, 2015-2025
    • 6.4.1. Anti-inflammatory Drugs
      • 6.4.1.1. NSAID
      • 6.4.1.2. Steroids
    • 6.4.2. Anti-infective Drugs
      • 6.4.2.1. Anti-fungal Drugs
      • 6.4.2.2. Anti-bacterial Drugs
      • 6.4.2.3. Others
    • 6.4.3. Anti-glaucoma Drugs
      • 6.4.3.1. Alpha Agonist
      • 6.4.3.2. Beta Blockers
      • 6.4.3.3. Prostaglandin Analogs
      • 6.4.3.4. Combined Medication
      • 6.4.3.5. Others
    • 6.4.4. Anti-allergy Drugs
    • 6.4.5. Anti-VEGF Agents
    • 6.4.6. Others
  • 6.5. Market Attractiveness by Therapeutic Class

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Key Trends
  • 7.4. Market Value Forecast by Product Type, 2015-2025
    • 7.4.1. Prescription Drugs
    • 7.4.2. OTC Drugs
  • 7.5. Market Attractiveness by Product Type

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Key Trends
  • 8.4. Market Value Forecast by Distribution Channels, 2015-2025
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Online Pharmacies
    • 8.4.3. Independent Pharmacies & Drug Stores
  • 8.5. Market Attractiveness by Distribution Channels

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Policies and Regulations
  • 9.3. Market Value Forecast by Region
    • 9.3.1. North America
    • 9.3.2. Europe
    • 9.3.3. Asia Pacific
    • 9.3.4. Latin America
    • 9.3.5. Middle East and Africa
  • 9.4. Market Attractiveness by Country/Region

10. North America Ophthalmic Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
    • 10.1.2. Policies and Regulations
    • 10.1.3. Key Trends
  • 10.2. Market Value Forecast by Disease Indication, 2015-2025
    • 10.2.1. Dry Eye
    • 10.2.2. Glaucoma
    • 10.2.3. Infection/Inflammation
    • 10.2.4. Retinal Disorders
      • 10.2.4.1. Wet AMD
      • 10.2.4.2. Dry AMD
      • 10.2.4.3. Diabetic Retinopathy
      • 10.2.4.4. Others
    • 10.2.5. Allergy
    • 10.2.6. Uveitis
    • 10.2.7. Others
  • 10.3. Market Value Forecast by Therapeutic Class, 2015-2025
    • 10.3.1. Anti-inflammatory Drugs
      • 10.3.1.1. NSAID
      • 10.3.1.2. Steroids
    • 10.3.2. Anti-infective Drugs
      • 10.3.2.1. Anti-fungal Drugs
      • 10.3.2.2. Anti-bacterial Drugs
      • 10.3.2.3. Others
    • 10.3.3. Anti-glaucoma Drugs
      • 10.3.3.1. Alpha Agonist
      • 10.3.3.2. Beta Blockers
      • 10.3.3.3. Prostaglandin Analogs
      • 10.3.3.4. Combined Medication
      • 10.3.3.5. Others
    • 10.3.4. Anti-allergy Drugs
    • 10.3.5. Anti-VEGF Agents
    • 10.3.6. Others
  • 10.4. Market Value Forecast by Product Type, 2015-2025
    • 10.4.1. Prescription Drugs
    • 10.4.2. OTC Drugs
  • 10.5. Market Value Forecast by Distribution Channels, 2015-2025
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Online Pharmacies
    • 10.5.3. Independent Pharmacies & Drug Stores
  • 10.6. Market Value Forecast by Country, 2015-2025
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Disease Indication
    • 10.7.2. By Therapeutic Class
    • 10.7.3. By Product Type
    • 10.7.4. By Distribution Channels
    • 10.7.5. By Country

11. Europe Ophthalmic Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
    • 11.1.2. Policies and Regulations
    • 11.1.3. Key Trends
  • 11.2. Market Value Forecast by Disease Indication, 2015-2025
    • 11.2.1. Dry Eye
    • 11.2.2. Glaucoma
    • 11.2.3. Infection/Inflammation
    • 11.2.4. Retinal Disorders
      • 11.2.4.1. Wet AMD
      • 11.2.4.2. Dry AMD
      • 11.2.4.3. Diabetic Retinopathy
      • 11.2.4.4. Others
    • 11.2.5. Allergy
    • 11.2.6. Uveitis
    • 11.2.7. Others
  • 11.3. Market Value Forecast by Therapeutic Class, 2015-2025
    • 11.3.1. Anti-inflammatory Drugs
      • 11.3.1.1. NSAID
      • 11.3.1.2. Steroids
    • 11.3.2. Anti-infective Drugs
      • 11.3.2.1. Anti-fungal Drugs
      • 11.3.2.2. Anti-bacterial Drugs
      • 11.3.2.3. Others
    • 11.3.3. Anti-glaucoma Drugs
      • 11.3.3.1. Alpha Agonist
      • 11.3.3.2. Beta Blockers
      • 11.3.3.3. Prostaglandin Analogs
      • 11.3.3.4. Combined Medication
      • 11.3.3.5. Others
    • 11.3.4. Anti-allergy Drugs
    • 11.3.5. Anti-VEGF Agents
    • 11.3.6. Others
  • 11.4. Market Value Forecast by Product Type, 2015-2025
    • 11.4.1. Prescription Drugs
    • 11.4.2. OTC Drugs
  • 11.5. Market Value Forecast by Distribution Channels, 2015-2025
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Online Pharmacies
    • 11.5.3. Independent Pharmacies & Drug Stores
  • 11.6. Market Value Forecast by Country, 2015-2025
    • 11.6.1. U.K.
    • 11.6.2. Germany
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Russia
    • 11.6.7. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Disease Indication
    • 11.7.2. By Therapeutic Class
    • 11.7.3. By Product Type
    • 11.7.4. By Distribution Channels
    • 11.7.5. By Country

12. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
    • 12.1.2. Policies and Regulations
    • 12.1.3. Key Trends
  • 12.2. Market Value Forecast by Disease Indication, 2015-2025
    • 12.2.1. Dry Eye
    • 12.2.2. Glaucoma
    • 12.2.3. Infection/Inflammation
    • 12.2.4. Retinal Disorders
      • 12.2.4.1. Wet AMD
      • 12.2.4.2. Dry AMD
      • 12.2.4.3. Diabetic Retinopathy
      • 12.2.4.4. Others
    • 12.2.5. Allergy
    • 12.2.6. Uveitis
    • 12.2.7. Others
  • 12.3. Market Value Forecast by Therapeutic Class, 2015-2025
    • 12.3.1. Anti-inflammatory Drugs
      • 12.3.1.1. NSAID
      • 12.3.1.2. Steroids
    • 12.3.2. Anti-infective Drugs
      • 12.3.2.1. Anti-fungal Drugs
      • 12.3.2.2. Anti-bacterial Drugs
      • 12.3.2.3. Others
    • 12.3.3. Anti-glaucoma Drugs
      • 12.3.3.1. Alpha Agonist
      • 12.3.3.2. Beta Blockers
      • 12.3.3.3. Prostaglandin Analogs
      • 12.3.3.4. Combined Medication
      • 12.3.3.5. Others
    • 12.3.4. Anti-allergy Drugs
    • 12.3.5. Anti-VEGF Agents
    • 12.3.6. Others
  • 12.4. Market Value Forecast by Product Type, 2015-2025
    • 12.4.1. Prescription Drugs
    • 12.4.2. OTC Drugs
  • 12.5. Market Value Forecast by Distribution Channels, 2015-2025
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Online Pharmacies
    • 12.5.3. Independent Pharmacies & Drug Stores
  • 12.6. Market Value Forecast by Country, 2015-2025
    • 12.6.1. India
    • 12.6.2. China
    • 12.6.3. Japan
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Disease Indication
    • 12.7.2. By Therapeutic Class
    • 12.7.3. By Product Type
    • 12.7.4. By Distribution Channels
    • 12.7.5. By Country

13. Latin America Ophthalmic Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
    • 13.1.2. Policies and Regulations
    • 13.1.3. Key Trends
  • 13.2. Market Value Forecast by Disease Indication, 2015-2025
    • 13.2.1. Dry Eye
    • 13.2.2. Glaucoma
    • 13.2.3. Infection/Inflammation
    • 13.2.4. Retinal Disorders
      • 13.2.4.1. Wet AMD
      • 13.2.4.2. Dry AMD
      • 13.2.4.3. Diabetic Retinopathy
      • 13.2.4.4. Others
    • 13.2.5. Allergy
    • 13.2.6. Uveitis
    • 13.2.7. Others
  • 13.3. Market Value Forecast by Therapeutic Class, 2015-2025
    • 13.3.1. Anti-inflammatory Drugs
      • 13.3.1.1. NSAID
      • 13.3.1.2. Steroids
    • 13.3.2. Anti-infective Drugs
      • 13.3.2.1. Anti-fungal Drugs
      • 13.3.2.2. Anti-bacterial Drugs
      • 13.3.2.3. Others
    • 13.3.3. Anti-glaucoma Drugs
      • 13.3.3.1. Alpha Agonist
      • 13.3.3.2. Beta Blockers
      • 13.3.3.3. Prostaglandin Analogs
      • 13.3.3.4. Combined Medication
      • 13.3.3.5. Others
    • 13.3.4. Anti-allergy Drugs
    • 13.3.5. Anti-VEGF Agents
    • 13.3.6. Others
  • 13.4. Market Value Forecast by Product Type, 2015-2025
    • 13.4.1. Prescription Drugs
    • 13.4.2. OTC Drugs
  • 13.5. Market Value Forecast by Distribution Channels, 2015-2025
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Online Pharmacies
    • 13.5.3. Independent Pharmacies & Drug Stores
  • 13.6. Market Value Forecast by Country, 2015-2025
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Disease Indication
    • 13.7.2. By Therapeutic Class
    • 13.7.3. By Product Type
    • 13.7.4. By Distribution Channels
    • 13.7.5. By Country

14. Middle East and Africa Ophthalmic Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
    • 14.1.2. Policies and Regulations
    • 14.1.3. Key Trends
  • 14.2. Market Value Forecast by Disease Indication, 2015-2025
    • 14.2.1. Dry Eye
    • 14.2.2. Glaucoma
    • 14.2.3. Infection/Inflammation
    • 14.2.4. Retinal Disorders
      • 14.2.4.1. Wet AMD
      • 14.2.4.2. Dry AMD
      • 14.2.4.3. Diabetic Retinopathy
      • 14.2.4.4. Others
    • 14.2.5. Allergy
    • 14.2.6. Uveitis
    • 14.2.7. Others
  • 14.3. Market Value Forecast by Therapeutic Class, 2015-2025
    • 14.3.1. Anti-inflammatory Drugs
      • 14.3.1.1. NSAID
      • 14.3.1.2. Steroids
    • 14.3.2. Anti-infective Drugs
      • 14.3.2.1. Anti-fungal Drugs
      • 14.3.2.2. Anti-bacterial Drugs
      • 14.3.2.3. Others
    • 14.3.3. Anti-glaucoma Drugs
      • 14.3.3.1. Alpha Agonist
      • 14.3.3.2. Beta Blockers
      • 14.3.3.3. Prostaglandin Analogs
      • 14.3.3.4. Combined Medication
      • 14.3.3.5. Others
    • 14.3.4. Anti-allergy Drugs
    • 14.3.5. Anti-VEGF Agents
    • 14.3.6. Others
  • 14.4. Market Value Forecast by Product Type, 2015-2025
    • 14.4.1. Prescription Drugs
    • 14.4.2. OTC Drugs
  • 14.5. Market Value Forecast by Distribution Channels, 2015-2025
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Online Pharmacies
    • 14.5.3. Independent Pharmacies & Drug Stores
  • 14.6. Market Value Forecast by Country, 2015-2025
    • 14.6.1. South Africa
    • 14.6.2. GCC Countries
    • 14.6.3. Rest of Middle East and Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Disease Indication
    • 14.7.2. By Therapeutic Class
    • 14.7.3. By Product Type
    • 14.7.4. By Distribution Channels
    • 14.7.5. By Country

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis by Company (2016)
  • 15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 15.3.1. Aerie Pharmaceuticals, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. ALLERGAN
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Valeant Pharmaceuticals International, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Bayer AG
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Novartis AG
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Pfizer Inc.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Regeneron Pharmaceuticals, Inc.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Santen Pharmaceutical Co., Ltd.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Shire
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths)
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Others

16. Key Take Aways

List of Tables

  • Table 01: Product Offering - Major Market Players
  • Table 02: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 03: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 04: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 05: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015-2025
  • Table 06: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015-2025
  • Table 07: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015-2025
  • Table 08: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 09: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 10: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 11: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 12: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 13: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 14: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 15: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015-2025
  • Table 16: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015-2025
  • Table 17: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015-2025
  • Table 18: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 19: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2015-2025
  • Table 20: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015-2025
  • Table 21: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 22: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 23: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 24: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2015-2025
  • Table 25: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2015-2025
  • Table 26: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2015-2025
  • Table 27: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 28: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 29: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • Table 30: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 31: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 32: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 33: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015-2025
  • Table 34: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015-2025
  • Table 35: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015-2025
  • Table 36: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 37: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 38: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015-2025
  • Table 39: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 40: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 41: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 42: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015-2025
  • Table 43: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015-2025
  • Table 44: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015-2025
  • Table 45: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 46: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 47: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2015-2025
  • Table 48: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 49: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2015-2025
  • Table 50: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class, 2015-2025
  • Table 51: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2015-2025
  • Table 52: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2015-2025
  • Table 53: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2015-2025
  • Table 54: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Product Type, 2015-2025
  • Table 55: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Figure 01: Global Ophthalmic Drugs Market Size (US$ Mn) Forecast, 2015-2025
  • Figure 02: Global Company Share: Anti-glaucoma Drugs, 2016
  • Figure 03: Global Causes of Blindness
  • Figure 04: U.S. - Causes of Blindness
  • Figure 05: Europe - Causes of Blindness
  • Figure 06: Japan Causes of Blindness
  • Figure 07: Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2025
  • Figure 08: Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
  • Figure 09: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2015-2025
  • Figure 10: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2015-2025
  • Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2015-2025
  • Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2015-2025
  • Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2015-2025
  • Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2015-2025
  • Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2015-2025
  • Figure 16: Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 17: Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
  • Figure 19: Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 18: Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 20: Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 21: Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 22: Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 23: Global Ophthalmic Drugs Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 24: Global Ophthalmic Drugs Market Value Share, by Product Type, for 2017 and 2025
  • Figure 25: Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 26: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2015-2025
  • Figure 27: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2015-2025
  • Figure 28: Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
  • Figure 29: Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2015-2025
  • Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2015-2025
  • Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2015-2025
  • Figure 33: Global Ophthalmic Drugs Market Value Share, by Region, for 2017 and 2025
  • Figure 34: Global Ophthalmic Drugs Market Attractiveness, by Region, 2017-2025
  • Figure 35: North America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 36: North America Ophthalmic Drugs Market Attractiveness, by Country, 2017-2025
  • Figure 37: North America Ophthalmic Drugs Market Value Share, by Country, 2017 and 2025
  • Figure 38: North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
  • Figure 39: North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
  • Figure 40: North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
  • Figure 41: North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 42: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
  • Figure 43: North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 44: North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2017 and 2025
  • Figure 45: North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels , 2017-2025
  • Figure 46: Europe Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 47: Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017-2025
  • Figure 48: Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
  • Figure 49: Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
  • Figure 50: Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
  • Figure 51: Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
  • Figure 52: Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 53: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
  • Figure 54: Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 55: Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 56: Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 57: Asia Pacific Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015-2025
  • Figure 58: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
  • Figure 59: Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2017 and 2025
  • Figure 60: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015-2025
  • Figure 61: Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2017 and 2025
  • Figure 62: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 63: Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2017 and 2025
  • Figure 64: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2017 and 2025
  • Figure 65: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 66: Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017 and 2025
  • Figure 67: Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 68: Latin America Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 69: Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017-2025
  • Figure 70: Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
  • Figure 71: Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2015-2025
  • Figure 72: Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
  • Figure 73: Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 74: Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
  • Figure 75: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
  • Figure 76: Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 77: Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 78: Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 79: Middle East & Africa Ophthalmic Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015-2025
  • Figure 80: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017-2025
  • Figure 81: Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017 and 2025
  • Figure 82: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017-2025
  • Figure 83: Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2017 and 2025
  • Figure 84: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017-2025
  • Figure 85: Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017 and 2025
  • Figure 86: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017 and 2025
  • Figure 87: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2017-2025
  • Figure 88: Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017 and 2025
  • Figure 89: Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017-2025
  • Figure 90: Global Ophthalmic Drugs Market Share, by Company, 2016
Back to Top